title: [Intravitreal ranibizumab (Lucentis®) in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy].
abstract: METHODS
  A 25 year old patient with high myopia diagnosed of metachronic choroidal neovascularisation in both eyes secondary to punctate inner choroidopathy leading to visual impairment and metamorphopsia. First eye was treated with four injections of ranibizumab after photodynamic therapy and the second eye only with charge dose of ranibizumab, reaching inactivity with good final visual acuity in both eyes.
  
  
  CONCLUSIONS
  Ranibizumab is useful in the treatment of this illness. Prospective studies are needed to investigate the usefulness of a combination with adjuvant therapies such as photodynamic therapy.
authors.affiliation: Licenciatura en Medicina, Unidad de Patología Macular, Hospital Clínico San Carlos, Madrid, España. valverdmegias@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Valverde Megías
authors.forename: P
authors.initials: P
authors.lastname: Arriola Villalobos
authors.forename: J
authors.initials: J
authors.lastname: Reche Frutos
authors.forename: J
authors.initials: J
authors.lastname: Donate López
authors.forename: C
authors.initials: C
authors.lastname: Calvo González
authors.forename: J
authors.initials: J
authors.lastname: García Feijoo
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D015862:Choroid Diseases / Q000150:complications*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab